抗抑郁药物向ST3GAL5-GM3脂质通路,以抑制微质炎症
Gaku Hayasaki1, Hiroto Izumi2,3, Yasuo Morimoto2,3
1Department of Psychiatry, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan.
International journal of molecular sciences
|October 16, 2025
概括
使用文拉法辛和伏尔托克塞丁治疗严重抑郁症会影响微质炎症信号传递. 这些抗抑郁药汇聚在ST3GAL5-GM3轴上,这表明了炎症相关抑郁症的新治疗标.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 大型抑郁症 (MD) 与慢性炎症和神经可塑性受损有关.
- 抗抑郁药作用的精确细胞机制尚未完全理解.
研究的目的:
- 调查文拉法辛 (VEN) 和伏尔素 (VOR) 对人类微质细胞的影响.
- 探索ST3GAL5-GM3脂质重塑轴在调节微质炎症信号传递中的作用.
主要方法:
- 用VEN,VOR或ST3GAL5过度表达 (ST3GAL5OE) 治疗的人类微质的转录组分析.
- 使用记者线 (NF-κB-RE-NlucP,SIE-NlucP) 的功能测试来评估炎症信号.
- 不同基因表达分析和通路丰富研究.
主要成果:
- VEN,VOR和ST3GAL5OE始终改变了基因表达,上调的基因与突触组织有关,下调的基因与炎症途径有关.
- VEN和VOR抑制了细胞因子诱导的NF-κB和STAT3激活,GM3治疗和ST3GAL5OE模仿的效果.
- 长期暴露于VEN或VOR显示出特定途径的抑制,汇聚在ST3GAL5-GM3轴上.
结论:
- ST3GAL5-GM3脂质重塑轴代表了一种新的调节途径,可以减弱微质炎症信号.
- 这一轴扩展了对抗抑郁药作用的理解,超出了传统的单氨基基模型.
- ST3GAL5-GM3轴可以作为炎症相关的MD的治疗标和生物标志物.
相关概念视频
01:23Antidepressant Drugs: MAOIs and Other Agents
806
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
806
01:25Antidepressant Drugs: Overview
1.4K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
1.4K
01:21G-protein Coupled Receptors
131.5K
G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
131.5K
01:22Alzheimer's Disease: Treatment
811
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
811
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
1.4K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
1.4K
01:27CNS Depressants: Alcohol and Nicotine
1.0K
Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...
1.0K